InvestorsHub Logo
Followers 443
Posts 63462
Boards Moderated 1
Alias Born 04/26/2007

Re: Redlegs post# 226

Monday, 05/23/2011 12:27:39 PM

Monday, May 23, 2011 12:27:39 PM

Post# of 1313
MCUJ - Recent clinical data from Europe may suggest AGGRASTAT may have advantages over the competition. Safety and cost benefits.

Will be interesting to see if/how Medicure addresses the most recent data with the FDA.

Market is about $1B in sales, just in US, for products used in the therapeutic space where AGGRASTAT is indicated, and where it may have a further role.

Please research all stocks before investing. My posts are my opinions and are not buy or sell recommendations. Always force market makers to cover their shorts above what you paid. Build wealth for fellow iHub'ers!